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ABSTRACT
Introduction: Previous series on the use of
daptomycin in enterococcal infective endo-
carditis (EIE) have shown various outcomes,
including higher mortality rates. We analyzed
the effectiveness of high-dose daptomycin for
the treatment of EIE.
Methods: We performed a prospective study
from 2010 to 2018 in a referral center in
patients with native (NVE) and prosthetic valve
endocarditis (PVE) due to Enterococcus spp. The
standard high-dose daptomycin at our institu-
tion is 10–12 mg/kg/day (CLCr[ 30 ml/min).
We compared the efficacy of a daptomycin-
based regimen (DBR) versus daptomycin-spar-
ing regimen (DSR) and daptomycin monother-
apy versus combination therapy. Primary
endpoints of the study were evaluation of risk
factors associated with 30-day mortality and
failure at end of therapy.
Results: We collected 43 EIE cases; 29 were NVE
(67.4%). Overall, 16 (37.2%) were treated with
DBR, mainly with combination regimens (11,
68.7%), in the majority of cases in association
with ß-lactam (7, 43.7%). The mean adminis-
tered dose of daptomycin was 10.125 mg/
kg/day (range 8–12 mg/kg/day). Overall,
patients treated with DBR compared with
patients treated with DSR had no higher mor-
tality rates and/or failure at end of therapy
(6.2% vs. 22. 2%; P 0.41 and MICs 0.25–2 mg/l,
6.2% vs. 3.7%; P 1.0). In the sub-group of
patients with NVE and PVE treated with DBR
and DSR, no difference was found regarding the
primary endpoints on the single or combined
use of daptomycin.
Conclusion: Our findings suggest that high-
dose daptomycin might be used as an alterna-
tive treatment regimen in EIE.
Keywords: Daptomycin; Enterococcal infective
endocarditis; Enterococcus spp.; High-dose
daptomycin
INTRODUCTION
Over the past decades, continuous changes in
epidemiologic and clinical characteristics of
infective endocarditis (IE) have shown that
enterococci have emerged as the third most
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common pathogen (10–15% of IE cases) fol-
lowing staphylococci and streptococci [1, 2].
Treatment of enterococcal IE (EIE) is known
to be challenging, because enterococci have
shown the ability to develop antibiotic resis-
tance with increasing high-level aminogly-
coside resistance (HLAR) and cure of IE usually
requires a prolonged course of antibiotics (up to
6 weeks) with potential adverse events [3, 4]. In
addition to established antimicrobials (ampi-
cillin plus ceftriaxone or ampicillin with
aminoglycosides), old (teicoplanin, van-
comycin) and novel antibiotics (dalbavancin)
have being investigated to improve the effec-
tiveness of antibacterial strategies [5–7].
Daptomycin is a cyclic lipopeptide antibiotic
with highly concentration-dependent bacteri-
cidal activity against gram-positive bacteria and
has been highly prescribed in the setting of
resistant enterococci [8]. Daptomycin was
approved for the treatment of right-sided
endocarditis caused by Staphylococcus aureus at a
dose of 6 mg/kg, although clinical and micro-
biologic data support improved efficacy at
higher doses [9]. In addition, several in vitro
studies and some case reports have demon-
strated synergistic activity against enterococci
with the combination of daptomycin and other
antibiotics [10, 11]. Daptomycin at higher doses
ranging from 8 to 14 mg/kg/day has been used
in EIE with variable and conflicting results,
including non-favorable microbiologic and
clinical response [12–14].
We have integrated the use of high-dose
([10 mg/kg) daptomycin [15] in monotherapy
or combination therapy in our treatment
armamentarium for EIE. The aim of this study is
to report the experience with daptomycin
compared with the standard treatment option
[3] at our institution.
METHODS
We performed a prospective 9-year study
(2010–2018) at the Santa Maria Misericordia
Hospital in Udine, a tertiary-care teaching hos-
pital (1000 beds) that is a referral regional center
for IE with a heart surgery department. All
consecutive adult patients ([18 years) with
native (NVE) and prosthetic valve endocarditis
(PVE) sustained by Enterococcus spp. were
included.
IE was defined according to the Duke’s
modified criteria. Indication for surgery was
based on ESC clinical guidelines [3].
Minimum inhibitory concentrations (MICs)
were determined by use of either E test or Sen-
sititre. MIC C 256 mg/l was recorded as HLAR
and MIC[ 4 mg/l as daptomycin non-suscep-
tible, in accordance with the European Com-
mittee on Antimicrobial Susceptibility Testing
(EUCAST) recommendations.
The standard recommended high dosage of
daptomycin in EIE at our institution is
10–12 mg/kg/day (10–12 mg/kg/48 h if
CLCr\30 ml/min, including hemodialysis and
CAPD) infused over 15 min [15].
Primary endpoints of the study were evalu-
ation of risk factors associated with 30-day
mortality rates and with failure at end of ther-
apy. We compared a daptomycin-based regimen
(DBR) vs. daptomycin-sparing regimen (DSR) as
a first-line or salvage therapy and daptomycin
monotherapy versus daptomycin used in
combination.
Patients were judged to have clinical failure if
they had no response to the antimicrobial treat-
ment based on ongoing fever, leukocytosis, other
clinical parameters and/or relapse of IE. Treat-
ment failure was defined as an inadequate
response to antibiotic with persistence of fever
and/or persistent bacteremia after 6 days of ade-
quate therapy, requiring an antibiotic change.
Quantitative variables were reported as the
mean (± standard deviation), and qualitative
variables were reported as number and per-
centage. Statistical analyses were performed
with SPSS-PC?, version 22.0 (SPSS, Chicago, IL).
The study was approved by the local institu-
tional review board.
All procedures performed in studies involving
human participants were in accordance with the
ethical standards of the University of Udine and
Azienda Sanitaria Universitaria Integrata di Udine
(IRB NR 505) and with the 1964 Helsinki Decla-
ration and its later amendments or comparable
ethical standards. The need for informed consent
was waived by the IRB because of the observa-
tional nature and minimal risk of the study.
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RESULTS
General Characteristics of the Cohort
and Strains
During the 8-year study period, enterococcal IE
accounted for 43 of 405 (10.6%) IE episodes,
including 29 NVE, (67.4%) and 14 PVE (32.6%).
The median age of the cohort was 67 years, and
29 (67.4%) patients were male. The main
comorbidities are shown in Table 1. There was
no statistically significant difference between
groups regarding baseline clinical characteris-
tics, except for diabetes.
Enterococcus faecalis accounted for 39 epi-
sodes (90.7%), while E. faecium for 4 (9.3%). All
strains treated with daptomycin were suscepti-
ble (MICs ranged from 0.25 to 4 mg/l), with 13
strains with MIC B 1 mg/l and 3 strains with
MIC 2–4 mg/l. Thirteen Enterococcus strains
Table 1 Demographic features, comorbidities, characteristics and outcome of 43 episodes of EIE treated with DCR and
DSR
Variables All, n 43 (%) DBR n 16 (%) DSR, n 27 (%) P
Age (years), mean ? SD 67.3 ± 15.6 67.1 ± 15.7 67.3 ± 15.5 0.81
Male 29 (67.4) 10 (62.5) 19 (70.4) 0.73
Underlying condition
Diabetes 8 (18.6) 6 (37.5) 2 (7.4) 0.04
Chronic renal failure 15 (34.8) 6 (37.5) 9 (33.3) 1.0
Transplantation 1 (2.3) 1 (6.2) 0 0.37
Neoplasm 3 (6.9) 2 (12.5) 1 (3.7) 0.54
Liver cirrhosis 1 (2.3) 0 1 (3.7) 0.31
COPD 5 (11.6) 3 (18.8) 2 (7.4) 0.3
Modified Charlson score, median (range) 4.4 ± 2.5 4.1 ± 2.9 4.5 ± 2.4 0.55
Type of IE
Native valve endocarditis 29 (67.4) 10 (62.5) 19 (70.4) 0.7
Prosthetic valve endocarditis 14 (32.5) 6 (37.5) 8 (29.6) 0.72
Heart valve affected
Aortic 31 (72.1) 11 (68.8) 20 (74.1) 0.69
Mitral 12 (27.9) 2 (12.5) 10 (37) 0.15
Right-sided IE 2 (4.6) 1 (6.2) 1 (3.7) 1.0
Complicationsa 6 (13.9) 3 (18.8) 3 (11.1) 0.5
Surgery performed 18 (41.8) 7 (43.7) 11 (40.7) 0.9
Duration of treatment 52 ± 22.6 45 ± 21.1 56 ± 23.2 0.02
30-Day mortality rate 7 (16.2) 1 (6.2) 6 (22.2) 0.41
Failure at the end of treatment 2 (4.6) 1 (6.2) 1 (3.7) 1.0
Bold value indicates statistical significance (p\0.05)
DBR daptomycin-containing regimen, DSR daptomycin-sparing regimen, IE infective endocarditis
a Complications: heart failure, new renal failure, embolism, paravalvular complications, stroke
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showed HLAR (12 E. faecalis and 1 E. faecium)
(Table 2).
Use of Daptomycin, Outcome
and Comparison
Of the 43 patients included in the study, 16
(37.2%) were treated with DBR, 14 (32.5%) were
ampicillin/gentamicin-treated patients, 9
(20.9%) were ampicillin/ceftriaxone-treated
patients, and the rest were patients with alter-
native regimens (2 with vancomycin, 1 with
linezolid, 1 with levofloxacin). Three of 16
patients in the DBR group (18.7%) had a history
of beta-lactam allergy. In the DBR group, dap-
tomycin combination therapy was performed in
11 patients (68.7%), in 6 cases (54.5%) in asso-
ciation with ampicillin, in 4 cases (36.5%) with
gentamicin and in the remaining case (9%) with
ceftaroline. The mean administered dose of
daptomycin was 10.125 mg/kg/day intra-
venously (range 8–12 mg/kg/day). Mean length
of antimicrobial therapy was 45 days in the DBR
group and 56 days in the DSR (P = 0.02). No
related adverse events (rhabdomyolysis and
eosinophilic pneumonia) occurred in patients
undergoing treatment with high-dose
daptomycin.
Overall surgery was performed in 41.8% of
patients (Tables 1, 2). All-cause mortality at
30 days was reported in seven (16.2%) patients.
Overall, patients treated with DBR compared
with patients treated with DSR had no higher
mortality rates and/or failure at end of therapy
(6.2% vs. 22. 2%; P = 0.41 and MICs 0.25–2 mg/l
6.2% vs. 3.7%; P = 1.0). In the sub-group of
patients with NVE and PVE treated with DBR
and DSR, no difference was found regarding the
primary endpoints on the single or combined
use of daptomycin (Table 2). There was only
one relapse in the DBR group.
DISCUSSION
To the best of our knowledge, this is the largest
series of enterococcal endocarditis patients
treated with a high-dose daptomycin regimen,
suggesting that it could be an alternative treat-
ment option for enterococcal NVE and PVE.
Our results are in contrast with previous
retrospective studies that found worse microbi-
ologic and clinical response in patients with EIE
treated with DBR [12]. Enterococcus spp. typi-
cally exhibit a higher in vitro MIC to dapto-
mycin than S. aureus, with a threshold for
susceptibility that is four times as high (B 4
vs. B 1 mg/l for S. aureus), and daptomycin
non-susceptibility among enterococci, currently
defined as MIC[ 4 mg/l, is a growing concern
[16]. In our study, all strains treated with dap-
tomycin were susceptible, with 13 strains with
MIC B 1 mg/l and 3 strains with MIC 2–4 mg/l.
Actually current CLSI guidelines have proposed
new breakpoints, suggesting that a breakpoint
B 1 lg/ml is likely more predictive of ‘‘true’’
susceptibility, particularly in endovascular
infections. In addition, for susceptible-dose
dependent strains (MIC 2–4 lg/Ml), increased
daptomycin doses (10–12 mg/kg/day) are rec-
ommended with potential consideration for
combination therapy [17].
In keeping with our center experience and
previous studies, to overcome this issue, two
approaches can be performed. On the one hand,
the use of higher dosing and then the use of
daptomycin combination therapy could influ-
ence the efficacy of daptomycin and also pre-
vent development of resistance leading to both
clinical and microbiologic failures [7, 15]. In our
study, most patients were treated with high
daptomycin doses (mean 10.125 mg/kg/day).
Probably the delayed response observed in pre-
vious studies on EIE could be explained by the
lower doses used (average dose of 8.5 mg/
kg/day) [12], since the use of increased dosage
has reported higher and more sustained killing,
including for E. faecium [14, 15, 18, 19].
In our series, most patients received combi-
nation therapy (68.7%), mainly in association
with ß-lactam (7, 43.7%) followed by amino-
glycoside (4, 25%). Several in vitro studies have
shown that daptomycin combination with ß-
lactam agents such as ampicillin, ceftriaxone
and ceftaroline/ceftobiprole could result in a
synergistic effect due to increased binding to
the cell membrane target [11, 20]. However, the
co-administration of gentamicin has not shown
a meaningful effect on the pharmacokinetic or
bactericidal activity of daptomycin on
Infect Dis Ther
Enterococcus spp. [21]. Of note, the emergence of
resistance has been shown to be delayed by ß-
lactam, but not by other antibiotics (gentamicin
and rifampin) [7].
Moreover, daptomycin is not altered in bio-
film bacteria in the stationary growth phase,
which makes it a major agent for the treatment
of EIE, including PVE [15]. Of note, in line with
previous literature, in our series, no patient
experienced daptomycin-induced muscle toxi-
city or eosinophilic pneumonia, despite the
high dosing regimen [22].
In our cohort, patients treated with DBR
compared with patients treated with DSR had a
trend toward lower mortality and a significantly
shorter treatment duration (45 days in the DBR
group and 56 days in the DSR; P = 0.02). Treat-
ment of EIE is known to be difficult, and med-
ical management is a challenge. In patients
undergoing heart surgery for IE, the optimal
length of antibiotic therapy after surgical exci-
sion is an unresolved issue. Current European
guidelines recommend administering the com-
plete course of treatment if the resected tissue is
culture-positive and completion of the
prescheduled course if it is culture-negative
[23]. In our center, we have a standardized
protocol for EIE. Patients with EIE receive a
complete 6-week course of treatment. The
duration of treatment is individualized accord-
ing to the complications of IE and the result of
valve culture. In patients who have undergone
valve replacement for IE, if valve culture is
negative, a 2-week postsurgical treatment
course in usually performed, and if the valve
culture is positive, a 4-week postsurgical treat-
ment course is usually performed.
The main limitations of this study are its
single-center design and the small sample size.
Second, a multivariate regression analysis
would have offered robust support, but we
found a statistical limitation related to the small
size of the cohort.
However, as far as we know, this is the largest
prospective series of EIE treated with high-dose
daptomycin. The sampling approach for select-
ing subjects for DBR was not random and was
subjective, but was performed by clinicians
involved in daily practice in EIE management
and reflects real-life practice in our center.
CONCLUSION
In conclusion, our findings suggest that high-
dosing daptomycin regimens could be used as
an alternative treatment option in enterococcal
NVE and PVE even in monotherapy. This strat-
egy deserves to be studied in prospective and
controlled clinical trials.
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